BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California. Show more

320 Soquel Way, Sunnyvale, CA, 94085, United States

Biotechnology

Healthcare

Market Cap

10.24M

52 Wk Range

$0.84 - $2.45

Previous Close

$0.90

Open

$0.92

Volume

144,250

Day Range

$0.88 - $0.96

Enterprise Value

10.07M

Cash

2.496M

Avg Qtr Burn

-2.497M

Insider Ownership

29.97%

Institutional Own.

7.13%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BCDA-01 CardiAMP cell therapy Details Ischemic stroke, Heart failure	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CardiAMP cell therapy Details Ischemic heart failure with reduced ejection fraction (HFrEF)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CardiAMP Autologous Cell Therapy (BCDA-02) (Cell Therapy) Details Chronic Myocardial Ischemia With Refractory Angina	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BCDA-03 CardiALLO cell therapy Details Ischemic stroke, Heart failure	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.